Amarin Corp Plc (AMRN)

[heysfguy]

Kiwi, very true:

"these data alone are not sufficient to influence therapeutic decisions .We await further study to conform these initial observations "

However, my point is that while this study is not conclusive, it is another significant entry onto the ever-growing list of indications that EPA has great CVD-related potential. FDA letters in the past have mentioned something to the effect of trying to stay abreast of contemporary developments in EPA-related research as they reach their decisions. More reason for them to consider expanded label, for instance.

You also commented earlier on EPA levels in blood being different for the Japanese population, but my reading is that the diffential of EPA levels was directly correlated to outcomes. Not so much a "how much" EPA there is as a population, but how different EPA levels match up with outcomes.

Anyway, your input is very good, I appreciate it.